
News|Slideshows|March 25, 2019
ACC.19: 3 Studies in Cardioprotection
Author(s)Veronica Hackethal, MD
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.
Advertisement
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Novo Nordisk Files NDA for CagriSema, Novel GLP-1-amylin Combination for Chronic Weight Management
2
Colorectal Cancer Screening in 2025: What Changed, and What Didn't, with Mark Fendrick, MD
3
GLP-1 RAs Carry Higher Risk of Serious GI Side Effects Than SGLT-2 Inhibitors: Daily Dose
4
Large National Claims Analysis Underscores Gap Between CGM Eligibility and Real-World Use in Diabetes Care
5
















































































































































































































































































